Dumont & Blake Investment Advisors LLC Increases Stock Position in CVS Health Corporation $CVS

Dumont & Blake Investment Advisors LLC boosted its stake in CVS Health Corporation (NYSE:CVS) by 149.0% in the first quarter, HoldingsChannel reports. The firm owned 14,798 shares of the pharmacy operator’s stock after acquiring an additional 8,854 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in CVS Health were worth $1,063,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Swiss RE Ltd. bought a new stake in CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC purchased a new stake in CVS Health in the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. bought a new stake in shares of CVS Health during the fourth quarter valued at approximately $28,000. Finally, Ares Financial Consulting LLC bought a new stake in CVS Health in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS opened at $102.13 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $106.15. The company has a market cap of $130.31 billion, a P/E ratio of 44.99, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The firm’s 50-day moving average price is $94.56 and its 200-day moving average price is $83.31.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. During the same period in the previous year, the firm posted $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is currently owned by insiders.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on CVS Health to $110 and maintained an overweight rating, signaling confidence in the company’s outlook and supporting the stock. Benzinga article
• Positive Sentiment: Recent commentary highlighted CVS Health as a momentum name and a healthcare outlier, with investors focused on its earnings beat, margin expansion potential, and turnaround progress. Seeking Alpha article
• Positive Sentiment: CVS Health Foundation announced a $1 million investment in Hartford nonprofits, which may modestly support the company’s community health image and ESG profile. Yahoo Finance article
• Neutral Sentiment: CVS Health said it will hold its second-quarter 2026 earnings conference call on August 5, keeping investors focused on upcoming results rather than changing fundamentals immediately. PR Newswire article
• Negative Sentiment: CVS medicated wipes were recalled over child safety concerns, a consumer-safety issue that could create reputational noise and weigh on sentiment. WBIW article
• Negative Sentiment: A separate report also noted the medicated wipes recall tied to child safety concerns, reinforcing the product-liability overhang. Yahoo News article

Analyst Ratings Changes

A number of research firms have issued reports on CVS. Piper Sandler reaffirmed an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. TD Cowen raised their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. DA Davidson boosted their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Bank of America increased their price objective on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Finally, Wall Street Zen cut shares of CVS Health from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Twenty-one analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $102.60.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.